Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
1 - 7 out of 7Page size: 10
  1. 2017
  2. Published

    Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jul 2017, In: B M J Open. 7, 7, 10 p., e015579.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jun 2017, In: Pharmacology Research & Perspectives. 5, 3, 9 p., e00317.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Detection of copy number alterations in cell-free tumor DNA from plasma

    Østrup, O., Ahlborn, L. B., Lassen, Ulrik Niels, Mau-Sørensen, M. & Nielsen, Finn Cilius, Jun 2017, In: BBA Clinical. 7, p. 120-126 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

    Urup, T., Staunstrup, L. M., Michaelsen, Signe Regner, Vitting-Seerup, K., Bennedbæk, M., Toft, A., Olsen, L. R., Jønson, L., Issazadeh-Navikas, Shohreh, Broholm, H., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 18 Apr 2017, In: BMC Cancer. 17, 10 p., 278.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols

    Ahlborn, L. B., Madsen, M., Jonson, L., Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W. & Mau-Sorensen, M., 2017, In: Clinical Laboratory. 63, 10, p. 1755-1759

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

    Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., Giménez-Capitán, A., Drozdowskyj, A., Viteri, S., Larsen, M. R., Lassen, Ulrik Niels, Felip, E., Bivona, T. G., Ditzel, H. J. & Rosell, R., 2017, In: Nature Communications. 8, 14 p., 410.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

    Meulendijks, D., Jacob, W., Voest, E. E., Mau-Sorensen, M., Martinez-Garcia, M., Taus, A., Fleitas, T., Cervantes, A., Lolkema, M. P., Langenberg, M. H. G., De Jonge, M. J., Sleijfer, S., Han, J-Y., Calles, A., Felip, E., Kim, S-W., Schellens, J. H. M., Wilson, S., Thomas, M., Ceppi, M. & 11 others, Meneses-Lorente, G., James, I., Vega-Harring, S., Dua, R., Nguyen, M., Steiner, L., Adessi, C., Michielin, F., Bossenmaier, B., Weisser, M. & Lassen, Ulrik Niels, 2017, In: Clinical Cancer Research. 23, 18, p. 5406-5415

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 4952653